​It has been found that FAK inhibitors as monotherapy may inhibit tumor adhesion and migration, but do not have a significant effect on the prognosis of patients with advanced cancer, and that combination therapies may buffer the toxicity of other therapies that trigger cancer cell death or immune response 92. This evidence concerns the gene PTK2 and cancer.